Ibex Biopharma
AI-powered biomarker development and quantification for drug development
Platform · HybridCompany source
Company profile
About Ibex Medical Analytics
Ibex Medical Analytics is a leading provider of AI-powered diagnostic solutions for cancer pathology, founded in 2016. The company has developed the most widely-deployed artificial intelligence platform in pathology, designed by pathologists for pathologists. Ibex's clinical-grade, multi-tissue platform helps pathologists detect and grade breast, prostate, and gastric cancers, along with more than a hundred other clinically relevant diagnostic features. The platform was developed from rich datasets extracted from over 10 million slides from pathology institutes around the world, with algorithms trained by diverse, global teams of senior pathologists using more than 150,000 image annotations and rigorous deep learning techniques. Ibex's solutions seamlessly integrate with third-party digital pathology software solutions, scanning platforms, and laboratory information systems to deliver automated high-quality insights that enhance patient safety, increase physician confidence, and boost productivity. The company serves the world's leading physicians, health systems, and diagnostic service providers, with field-proven technology that has demonstrated outstanding outcomes in rigorous worldwide clinical studies. Ibex has recently expanded its clinical-grade AI platform into biopharma, supporting early translational research, biomarker development, and late-stage biomarker development to accelerate drug development pipelines and enhance trial efficiency.
Company description Ibex Medical Analytics official website
Mission. To transform pathology by ensuring that every patient can receive an accurate, timely and personalized cancer diagnosis.
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Work at Ibex Medical Analytics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Breast cancer
- Gastric cancer
- Lung cancer
- Over 100 diagnostic features across multiple tissue types
- Prostate cancer
- Various cancer subtypes and grades
Who it serves
- Academic medical centers
- Biopharma companies
- Diagnostic service providers
- Health systems
- Pathology institutes
Deployment & integration
Hybrid deployment with recorded integration context.
Recorded integration context: Image management systems, Multiple whole slide imaging scanners, PathPresenter, Philips digital pathology, Roche, Various LIS systems.
Geographic context
MarketsBrazil · Europe (CE marked) · Global deployment · United Kingdom · United States (RUO only)
Company sourceOfficial website
Company milestones
Platform expansion
Expansion into biopharma for early translational research and biomarker development. Partnership expansion with Philips. Collaboration with Roche and AWS. Series B funding of $38 million mentioned.
Partnerships
Recorded partners
- Amazon Web Services
- Multiple LIS providers
- Multiple whole slide imaging scanner manufacturers
- PathPresenter
- Philips
- Roche
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Ibex Breast HER2
AI-powered HER2 biomarker analysis for breast cancer
Software · HybridCompany source
Ibex Breast Suite
AI-powered breast cancer detection and diagnostic feature analysis
Software · HybridCompany source
Ibex First Read for Prostate
First-read AI solution for prostate cancer screening and prioritization
Software · HybridCompany source
Ibex Gastric
AI-powered gastric cancer detection and classification
Software · HybridCompany source
Ibex Platform
AI-powered multi-tissue pathology platform for cancer detection and grading
Platform · HybridCompany source
Ibex Prostate
AI-powered prostate cancer detection with Gleason grading and feature analysis
Software · HybridCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Regulatory science for AI-based software as a medical device in computational pathology and biomarker-driven drug development.Journal of pathology informatics · Aug 1, 2026
An artificial intelligence solution for evaluation of prostate needle core biopsy specimens: impact in a non-specialist setting.Virchows Archiv : an international journal of pathology · Jun 3, 2026
A Comprehensive AI-Based Approach in Classifying Breast Lesions: Focusing on Improving Pathologists' Accuracy and Efficiency.Clinical breast cancer · Aug 1, 2025
Fully Automated Artificial Intelligence Solution for Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Scoring in Breast Cancer: A Multireader Study.JCO precision oncology · Oct 1, 2024
Validation of prostate and breast cancer detection artificial intelligence algorithms for accurate histopathological diagnosis and grading: a retrospective study with a Japanese cohort.Pathology · Aug 1, 2024
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies.NPJ breast cancer · Dec 6, 2022
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Galen Second ReadK241232 · 510k · Jan 24, 2025
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Near perfect concordance with consensus diagnosis between pathologists
Ibex Breast study at Institut Curie
Area under the curve close to near perfect
Prostate solution validation study
Enhanced physician confidence and patient safety
General platform outcomes
Faster diagnosis and lower pathology workloads
Workflow efficiency
Higher quality, more targeted care
Clinical outcomes
Betsi Cadwaladr University Health Board, Wales
AI-assisted diagnosis of prostatic cores for correct and reproducible tissue diagnosis across pathology team
Enhanced confidence in making correct and reproducible tissue diagnosis by entire pathology team
Brigham and Women's Hospital
Implementation of Ibex Breast for accuracy and broad detection capabilities in pathology workflows
Transformed pathologists' work through accuracy and broad detection capabilities
Institut Curie, Paris
Validation of Ibex Breast for cancer diagnosis, invasive carcinoma typing, and nuclear grading of in situ carcinomas
Near perfect concordance with consensus diagnosis between pathologists
The University of Tennessee Health Science Center
Detection of small foci of cancer and higher-grade cancers for prospective quality control
Ability to detect small foci of cancer that can be missed and identify higher-grade cancers
University of Pittsburgh Medical Center (UPMC)
Validation study of Ibex Prostate solution for cancer diagnosis, Gleason grading, tumor sizing and perineural invasion detection
Area under the curve close to near perfect for cancer diagnosis and clinically relevant features
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Ibex Medical Analytics
Recent articles published on Ibex Medical Analytics's official website.
Ibex Medical Analytics Establishes Biopharma Advisory Board to Advance AI-Powered Precision Diagnostics
Read on Ibex Medical AnalyticsCorePlus and Ibex Expand Partnership with Clinical Deployment of AI-Powered Diagnostics for TURP
Read on Ibex Medical AnalyticsIbex Expands U.S. Footprint with HNL Lab Medicine Partnership to Deploy Clinical-Grade AI to Support Cancer Diagnostics
Read on Ibex Medical AnalyticsIbex Medical Analytics Unveils Ibex 4, the Next-Generation AI Platform Setting a New Standard in Comprehensive Cancer Diagnostics and Patient Care
Read on Ibex Medical AnalyticsIbex Medical Analytics and mTuitive Announce Strategic Partnership to Transform Digital Pathology with AI-Enhanced Structured Reporting
Read on Ibex Medical Analytics07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
AI Pathology Platform Achieves Full European Clearance for Breast Cancer Biomarker Suite
Ibex Medical Analytics completes IVDR certification across five critical diagnostic markers, positioning unified platform as comprehensive alternative to single-biomarker competitors.
Clinical AI · Jul 25, 2026
AI Pathology Tool Catches Diagnostic Errors in 5% of Prostate Biopsies in Major NHS Trial
Real-world study across three UK health trusts shows Tempus's AI software reduced turnaround times by nearly a day while prompting clinically significant diagnostic changes in over 1% of cases.
Clinical AI · Jul 17, 2026
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.